Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data…

Real-world retrospective data from Italy suggests that people with MS treated with gilenya (fingolimod) have fewer relapses than those treated with rebif (IFN-β1a) 44 µg three times weekly https://t.co/NKLbqLcLje